Information Provided By:
Fly News Breaks for April 26, 2017
NUVA
Apr 26, 2017 | 08:19 EDT
Canaccord analyst Kyle Rose noted NuVasive posted mixed Q1 results as international momentum offset softer than expected U.S. revenues. The full year guidance was maintained but he believes upside remains with the potential for margin expansion, its taking market share in the global spine market, new product flow, and tailwinds such as vendor consolidation. Rose reiterated his Buy rating and raised his price target to $84 from $82 on NuVasive shares.
News For NUVA From the Last 2 Days
There are no results for your query NUVA